Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer

Table 1 SHP-2 expression in 83 paired gastric cancers and adjacent normal mucus and SHP-2 by Helicobacter pylori infection in gastric cancer groups n (%)

	H-score				Median H-score (quartile)	P value
	0	1-99	100-200	201-300
Cancer (n = 83)	10 (12.0)	21 (25.3)	27 (32.5)	25 (30.1)	160 (40-210)	< 0.001
Control (n = 83)	41 (49.4)	15 (18.1)	21 (25.3)	6 (7.2)	20 (0-160)
Positive (n = 67)	8 (11.9)	8 (11.9)	24 (35.8)	27 (40.3)	180 (120-270)	0.401
Negative (n = 33)	1 (3.0)	10 (30.3)	11 (33.3)	11 (33.3)	160 (85-240)

Table 2 SHP-2 expressions and clinical characteristics of 305 gastric cancer patients

	H-score, n (%)				Median H-score (quartile)	P value
	0	1-99	100-200	201-300
Sex
Male (n = 233)	16 (6.9)	44 (18.9)	79 (33.9)	94 (40.3)	160 (100-240)	0.82
Female (n = 72)	4 (5.6)	8 (11.1)	36 ( 50.0)	24 (33.3)	160 (140-240)
Age
≤ 60 yr (n = 129)	9 (7.0)	23 (17.8)	50 (38.8)	47 (36.4)	160 (110-240)	0.92
> 60 yr (n = 176)	11 (6.3)	29 (16.5)	65 (36.9)	71 (40.3)	180 (110-240)
Differentiation
Well (n = 6)	0 (0)	1 (16.7)	1 (16.7)	4 (66.7)	225 (155-270)	0.43
Moderate (n = 114)	8 (7.0)	20 (17.5)	41 (36.0)	45 (39.5)	160 (115-240)
Poor (n = 185)	12 (6.5)	31 (16.8)	73 (39.5)	69 (37.3)	160 (120-240)
Lymph-vascular invasion
No (n = 142)	9 (6.3)	22 (15.5)	54 (38.0)	57 (40.1)	160 (120-240)	0.89
Yes (n = 163)	11 (6.7)	30 (18.4)	61 (37.4)	61 (37.4)	160 (100-240)
Nerve invasion
No (n = 184)	14 (7.6)	30 (16.3)	70 (38.0)	70 (38.0)	160 (120-240)	0.40
Yes (n = 121)	6 (5.0)	22 (18.2)	45 (37.2)	48 (39.7)	160 (120-240)
TNM staging
I (n = 25)	0 (0)	3 (12.0)	12 (48.0)	10 (40.0)	180 (140-270)	0.34
II (n = 50)	4 (8.0)	8 (16.0)	13 (26.0)	25 (50.0)	195 (115-270)
III (n = 194)	14 (7.2)	32 (16.5)	77 (39.7)	71 (36.6)	160 (120-240)
IV (n = 36)	0 (0)	7 (20.6)	14 (41.2)	13 (38.2)	160 (100-242)
Invasion
T1 (n = 9)	0 (0)	0 (0)	4 (44.4)	5 (55.6)	240 (170-270)	0.34
T2 (n = 37)	1 (2.7)	7 (18.9)	18 (48.6)	11 (29.7)	160 (120-225)
T3 (n = 225)	19 (8.4)	38 (16.9)	79 (35.1)	89 (39.6)	160 (100-240)
T4 (n = 34)	0 (0)	7 (20.6)	14 (41.2)	13 (38.2)	160 (120-248)
Lymph node metastases
N0 (n = 66)	3 (4.5)	10 (15.2)	23 (34.8)	30 (45.5)	180 (140-270)	0.17
N1 (n = 94)	7 (7.4)	15 (16.0)	31 (33.0)	41 (43.6)	180 (120-240)
N2 (n = 79)	3 (3.8)	15 (19.0)	39 (49.4)	22 (27.8)	160 (120-210)
N3 (n = 66)	7 (10.6)	12 (18.2)	22 (33.3)	25 (37.9)	160 (100-270)
Distant metastasis
No (n = 266)	18 (6.8)	43 (16.2)	101(38.0)	104 (39.1)	170 (120-240)	0.52
Yes (n = 39)	2 (5.1)	9 (23.1)	14 (35.9)	14 (35.9)	160 (100-240)
Survival
Survived (n = 180)	12 (6.7)	28 (15.6)	69 (38.3)	71 (39.4)	180 (120-240)	0.77
Died (n = 125)	8 (6.4)	24 (19.2)	46 (36.8)	47 (37.6)	160 (100-240)

TNM: Tumor node metastasis.

Table 3 Multivariate analyses for disease-specific survival

	RR (95% CI)	P value
SHP-2 expression
H-score (201-300) (n = 118)
H-score (100-200) (n = 115)	0.99 (0.63-1.56)	0.98
H-score (1-99) (n = 52)	1.08 (0.72-1.64)	0.70
Negative (0) (n = 20)	1.04 (0.49-1.67)	0.82
Tumor node metastasis staging
I (n = 25)
II (n = 51)	1.87 (0.52-6.79)	0.34
III (n = 195)	3.94 (1.22-12.74)	0.02
IV (n = 34)	13.63 (4.04-46.06)	0.00
Lymph-vascular invasion
Yes (n = 142)
No (n = 163)	1.61 (1.09-2.37)	0.02

Calculated by age, sex, differentiation, lymph-vascular invasion and tumor node metastasis staging adjusted Cox regression model. RR: Relative risk.